Sep 5, 2017 - Insmed Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS (Amikacin Liposome Inhalation Suspension) in Adult Patients with Treatment-Refractory (NTM) Lung Disease

David Schnell

September 5, 2017